STOCK TITAN
  1. Home
  2. Sec-filings
  3. EDSA
  4. [Form 4] Edesa Biotech, Inc. Insider Trading Activity

Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported a compensation-related stock grant. He received 3,378 restricted share units of Edesa Biotech common shares at no cost, which vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan.

Following this award, he directly holds 888,062 common shares. The filing also lists indirect common share holdings held through entities such as Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015, for which he reports positions but disclaims full beneficial ownership beyond his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Nijhawan Pardeep
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Shares 3,378 $0.00 --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 888,062 shares (Direct, null); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation)
Footnotes (1)
  1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
RSU grant size 3,378 shares Restricted share units granted, vested in full upon grant
Grant price $0.00 per share Price for restricted share units under 2019 Equity Incentive Compensation Plan
Direct holdings after grant 888,062 shares Common shares directly held by CEO following RSU award
Indirect via 1968160 Ontario Inc. 53,104 shares Common shares held indirectly through 1968160 Ontario Inc.
Indirect via Digestive Health Clinic Inc. 32,013 shares Common shares held indirectly through The Digestive Health Clinic Inc.
Indirect via family trust 32,609 shares Common shares held indirectly by The New Nijhawan Family Trust 2015
Indirect via Medicine Professional Corp. 402,702 shares Common shares held indirectly by Pardeep Nijhawan Medicine Professional Corporation
restricted share units financial
"Reflects a grant of restricted share units, which vested in full upon grant"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
2019 Equity Incentive Compensation Plan financial
"vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
co-trustee financial
"Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nijhawan Pardeep
(Last)(First)(Middle)
C/O EDESA BIOTECH INC.
100 SPY COURT
(Street)
MARKHAML3R 5H6
(City)(State)(Zip)
ONTARIO, CANADA
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares07/02/2026A3,378(1)A$0(1)888,062D
Common Shares402,702IHeld by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares32,609IHeld by The New Nijhawan Family Trust 2015(3)
Common Shares32,013IHeld by The Digestive Health Clinic Inc.(2)
Common Shares53,104IHeld by 1968160Ontario Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Edesa Biotech (EDSA) CEO Pardeep Nijhawan report in this Form 4?

He reported a grant of 3,378 restricted share units of Edesa Biotech common shares, which vested immediately. The filing also updates his direct and indirect shareholdings across several related entities and a family trust.

How many Edesa Biotech (EDSA) shares does the CEO hold directly after this grant?

After the grant, Pardeep Nijhawan holds 888,062 Edesa Biotech common shares directly. This reflects the addition of 3,378 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan.

What is the size and nature of the CEO’s new equity award at Edesa Biotech (EDSA)?

He received 3,378 restricted share units of common shares at a price of $0.00 per share. These units vested in full immediately on grant, indicating a compensation award rather than an open-market purchase of stock.

Which indirect holdings are associated with Edesa Biotech (EDSA) CEO Pardeep Nijhawan?

Indirect holdings are reported through 1968160 Ontario Inc., The Digestive Health Clinic Inc., Pardeep Nijhawan Medicine Professional Corporation, and The New Nijhawan Family Trust 2015. He disclaims full beneficial ownership except to the extent of his pecuniary interest.

Did the Edesa Biotech (EDSA) CEO buy or sell shares on the open market in this Form 4?

The filing shows a grant of 3,378 restricted share units that vested immediately, not an open-market trade. Other entries reflect updated indirect holdings, with no reported open-market purchases or sales in this data.

What is the role of the 2019 Equity Incentive Compensation Plan at Edesa Biotech (EDSA) in this filing?

The plan is the source of the CEO’s 3,378 restricted share unit grant. The units vested in full upon grant under the 2019 Equity Incentive Compensation Plan, highlighting its use for executive equity compensation.